SOLUTION
Although instances of what we call ‘rare diseases’, particularly genetic disorders, are – by their very nature – rare on an individual basis, there are numerous diverse rare disorders. This means that about 1 in 10 of the global population have a so-called ‘rare disease’.
At Jameel Health we’re proud to have expanded our ability to bring treatments in this area to the global south through our recent acquisition of Genpharm, in 2022.
الشريك المميز
Genpharm provides fast-track market access to rare disease and specialty pharmaceutical companies looking to expand into the Middle East and North Africa and Turkey. It is the regional leader in rare diseases and one of the only regional companies to have gene therapy expertise.
Founded in 2012, it, has bases in the Dubai Science Park, UAE; an office in Boston, USA, in the heart of the biotech hub and in Ireland. Operating through evidence-based medicine and the highest ethical standards, Genpharm provides its partners with fast and sustainable market access solutions into the MENA region.
In 2022, its 10th anniversary year, Jameel Health acquired Genpharm expanding our distribution infrastructure and also portfolio with Genpharm’s specialism in rare disease therapies.
انظر جميع الشركاء
